MedTrace Logo

A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT07638566 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-06-10

No results posted yet for this study

Summary

The main purpose of the study is to determine the correct dose of empasiprubart in adolescent participants. It also aims to evaluate if empasiprubart may work and how safe it is for the use in children living with CIDP.

The study consists of an open label treatment phase where participants will receive empasiprubart for up to 27 months approximately. After the final dose of empasiprubart, participants will enter a safety follow-up period for up to 14 months approximately.

The overall study duration for each participant is up to 43 months.

More information can be found here: clinicaltrials.argenx.com/emlight

Conditions

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
  • CIDP
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Interventions

BIOLOGICAL

Empasiprubart IV

Intravenous infusions of empasiprubart

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-04-30
Completion
2031-08-31
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07638566 on ClinicalTrials.gov